Amgen Delivers Strong Q2 2025 Results Amidst Industry Challenges
Highlights
- Revenue: $9.2 billion (+9% YoY)
- Volume growth: 13%
- Repatha sales: $696 million (+31% YoY)
- EVENITY sales: $518 million (+32% YoY)
- TEZSPIRE sales: $342 million (+46% YoY)
- Rare disease portfolio: nearly $1.4 billion (+19% YoY)
- Biosimilar portfolio: $661 million (+40% YoY)
- Prolia sales: $1.1 billion (-4% YoY)
Amgen has announced robust financial results for the second quarter of 2025, reflecting its strategic focus on volume growth across a diverse portfolio of products, even as the biopharmaceutical sector grapples with pricing pressures.
Sustained Revenue and Volume Growth
Amgen's Q2 revenue reached $9.2 billion, marking a 9% increase compared to the previous year. This growth was primarily driven by a significant 13% rise in sales volume. The results underline Amgen’s ability to capitalize on market demand despite challenges such as declining net selling prices across the industry.
Key Product Performances
Repatha and EVENITY were pivotal to driving growth. Repatha’s sales soared by 31% to $696 million, supported by increased patient access and ongoing direct-to-consumer campaigns. EVENITY also showed impressive growth, with sales reaching $518 million, a 32% year-over-year increase, particularly driven by the U.S. market.
TEZSPIRE continued its strong performance with a 46% increase in sales, highlighting the expanding use of biologic agents in severe asthma. Meanwhile, Amgen’s rare disease portfolio grew 19% year-over-year to nearly $1.4 billion, underscoring the success of products like TEPEZZA and UPLIZNA, which saw significant market penetration.
Biosimilars and Market Dynamics
The company's biosimilar portfolio experienced a notable 40% increase in sales to $661 million, reaffirming Amgen’s strategic emphasis on this sector. This growth illustrates the successful adoption of biosimilars in the market, contributing significantly to the company's top-line growth.
Challenges and Market Adjustments
Despite the overall positive performance, Prolia faced a decline in sales by 4%, primarily due to lower net selling prices. This indicates ongoing challenges with pricing pressures in some segments.
Overall, Amgen’s Q2 2025 results demonstrate its strong operational execution and strategic product positioning amidst a challenging industry environment. While navigating pricing pressures and market dynamics, the company's diverse portfolio continues to drive growth and sustain its competitive edge.